It was a busy and inspiring day for Occuity — welcoming Beth White from the Office for Life Sciences to our Reading HQ before heading to Lancaster House for a celebration of UK–India relations. A proud moment to reflect on how far we’ve come and the global impact our innovation can have.

As Occuity opens its latest crowdfunding round on Republic Europe, we spoke with existing investor Chris Gibbs about what drew him to support the company and how he sees its potential. “I love the tech. The science nerd in me thinks it is very cool.” Chris Gibbs, Occuity Shareholder Chris works as a freelance consultant in medical device product development and has previously held roles across R&D in a range of MedTech companies, from start-ups to global businesses. He holds

At Occuity, our mission is to create elegant, non-contact optical devices that bring advanced diagnostic capabilities into everyday healthcare settings. To achieve this, we invest deeply in research and development, pioneering new approaches in optical engineering. Central to this work is our intellectual property, which protects the originality of our technology and supports our global expansion. Occuity is a very innovative company with a very talented team of engineers, an

Occuity CEO, Dr. Dan Daly joins UK Prime Minister Sir Keir Starmer on the official UK Government Trade Delegation to India

Reflections on a Proud Moment for Occuity - Attending the Royal Academy of Engineering’s annual awards - as recipients of the 2025 Colin Campbell Mitchell Award for our work on the PM1 Pachymeter,

Occuity AX1 receives a great deal of interest at ESCRS for the measurement of axial length in myopia management

We are pleased to share that Occuity  has been invited to present at the upcoming Ophthalmology Futures European Forum 2025 , taking...

Following our great success last year in Barcelona, we are pleased to announce that Occuity will again be available for meetings, this...

Occuity Partners with Paneca Technologies as Exclusive Distributor in Turkey.

Following a year of major progress — including the launch of our first revenue-generating product, the PM1 Pachymeter, the expansion of our global distribution network, and significant technical advances across our roadmap — we're excited to announce the launch of Occuity’s new investment round.

Occuity Recognised in Landmark £6 billion UK-India Trade Announcement

Jason Higginbotham discussing the Occuity PM1 and AX1 at AECOS London Symposium 2025

Occuity , is pleased to announce that Remidio Innovative Solutions , a leading manufacturer and distributor of ophthalmic medical...

In this video blog, Richard Kadri-Langford, Head of Marketing at Occuity, demonstrates the AX1 Axiometer on his own children to show how quick, accurate and child-friendly the device is for myopia management. With no chin rest, no contact and rapid results, the AX1 is designed to make axial length measurement easier for clinicians and more comfortable for young patients.

New Study Highlights Importance of Corneal Centre Thickness (CCT) in Glaucoma Screening.

The joy of unboxing a new toy isn’t just for children — sometimes, it’s for researchers too! This time, the toy in question was the...

Occuity is working at the cutting edge of ophthalmological instrumentation, developing machines that have never existed before both as...

Occuity secures CE Marking for PM1 Pachymeter: A Major Milestone for the Company

At Occuity, we’re delighted to announce an exciting new partnership that will extend the reach of our cutting-edge ophthalmic devices....

Occuity awarded prestigious title of National Medtech & Healthtech StartUp of the Year at UK StartUp Awards